Kelly A. Byrnes-Blake, Ph.D.
Affiliations: | 2001 | University of Arkansas for Medical Sciences, United States |
Area:
Pharmacology, ImmunologyGoogle:
"Kelly Byrnes-Blake"Mean distance: (not calculated yet)
Parents
Sign in to add mentor| S. Michael Owens | grad student | 2001 | UAMS | |
| (Mechanistic studies toward the development of antibody -based medications for (+)-methamphetamine abuse.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Parrish-Novak J, Byrnes-Blake K, Lalayeva N, et al. (2017) Nonclinical Profile of BLZ-100, a Tumor-Targeting Fluorescent Imaging Agent. International Journal of Toxicology. 36: 104-112 |
| Burge DJ, Eisenman J, Byrnes-Blake K, et al. (2016) Safety, pharmacokinetics, and pharmacodynamics of RSLV-132, an RNase-Fc fusion protein in systemic lupus erythematosus: a randomized, double-blind, placebo-controlled study. Lupus |
| Byrnes-Blake KA, Pederson S, Klucher KM, et al. (2012) Pharmacokinetics and pharmacodynamics of pegylated interferon lambda-1 in cynomolgus monkeys. Journal of Interferon & Cytokine Research : the Official Journal of the International Society For Interferon and Cytokine Research. 32: 198-206 |
| Mabry R, Lewis KE, Moore M, et al. (2010) Engineering of stable bispecific antibodies targeting IL-17A and IL-23. Protein Engineering, Design & Selection : Peds. 23: 115-27 |
| Ellsworth JL, Hamacher N, Harder B, et al. (2009) Recombinant soluble human FcgammaR1A (CD64A) reduces inflammation in murine collagen-induced arthritis. Journal of Immunology (Baltimore, Md. : 1950). 182: 7272-9 |
| Ellsworth JL, Maurer M, Harder B, et al. (2008) Targeting immune complex-mediated hypersensitivity with recombinant soluble human FcgammaRIA (CD64A). Journal of Immunology (Baltimore, Md. : 1950). 180: 580-9 |
| Milesi-Hallé A, McMillan DE, Laurenzana EM, et al. (2007) Sex differences in (+)-amphetamine- and (+)-methamphetamine-induced behavioral response in male and female Sprague-Dawley rats. Pharmacology, Biochemistry, and Behavior. 86: 140-9 |
| Byrnes-Blake KA, Laurenzana EM, Landes RD, et al. (2005) Monoclonal IgG affinity and treatment time alters antagonism of (+)-methamphetamine effects in rats. European Journal of Pharmacology. 521: 86-94 |
| Laurenzana EM, Byrnes-Blake KA, Milesi-Hallé A, et al. (2003) Use of anti-(+)-methamphetamine monoclonal antibody to significantly alter (+)-methamphetamine and (+)-amphetamine disposition in rats. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 31: 1320-6 |
| Byrnes-Blake KA, Laurenzana EM, Carroll FI, et al. (2003) Pharmacodynamic mechanisms of monoclonal antibody-based antagonism of (+)-methamphetamine in rats. European Journal of Pharmacology. 461: 119-28 |